Contrast Media Injectors Market Trend, Gross Earning and Emerging Growth Opportunity by 2033 | FMI
The Contrast Media Injectors Market is expected to be sold this year, 2023, is estimated to be around US$ 1.6 billion. Furthermore, the global contrast media injector market is expected to reach approximately US$ 3 billion by 2033, with a 6.6% annual growth rate.
Increasing trauma cases globally is expected to boost the growth of the
contrast media injectors market. Additionally, the increasing prevalence of
cancer among the geriatric population globally is expected to drive demand for
the contrast media injectors market.
Gain complete access to the report @ https://www.futuremarketinsights.com/reports/contrast-media-injectors-market
Furthermore, as the number of cancer, neurological, and cardiovascular patients
admitted to hospitals rises, the industry will experience significant growth.
With the vast range of applications in radiology, interventional radiology, and
interventional cardiology, hospitals are the principal users of high-pressure
contrast media injectors.
End-user demand for technologically improved contrast media injectors,
such as IT-enabled contrast media injectors that can connect to a hospital
database for dosage monitoring, is driving up contrast media injector prices.
Air emboli formed during contrast media injection can restrict right
ventricular outflow or clog pulmonary arterioles, resulting in significant
complications such as cardiovascular collapse.
Radiographic
contrast injectors are medical devices that are used to inject contrast
media into a patient's body for medical imaging procedures such as CT scans,
MRI scans, and angiography. Contrast media is a substance that helps enhance
the visibility of certain organs or tissues during these procedures.
Key Takeaways from the Contrast Media Injectors Market Study Report
The United States is the leading market with a market share of 32.5%,
which is around US$ 500 Million in 2023. The demand for contrast media
injectors in the country is projected to grow at a rate of 6.8% from 2023 to
2033.
In Europe, Germany is the dominant market and is projected to register a
CAGR of 6.3% from 2023 to 2033. It is the second-largest market in the world
and is predicted to reach US$ 202.9 Million by the end of 2033.
While. the demand for contrast media injectors in the United Kingdom is
growing faster than in Germany. The report predicts the growth rate for the UK
market to be 6.4% through 2033 to reach a valuation of US$ 123.3 Million.
Meanwhile, China is the fastest-growing region in the production and
sales of contrast media injectors around the world. By registering a CAGR of
7.8% over the forecast years, this regional market is estimated to reach US$
192.3 Million by 2033.
India is emerging as a promising market with growing demand for contrast
media injectors. The growth rate estimated for this regional market is around
5.4%, and the net worth of the market is to reach US$ 42.5 Million by 2033.
Among the different types of contrast media injectors available in the
market, CT injectors are the top-performing product type segment. This segment
is projected to grow at a rate of 6.4% during the time period covering 2023 to
2033.
For the contrast media injectors market players, the hospital segment is
predicted to remain the prominent end-user vertical. During the forecast
period, this segment is expected to witness a year-on-year growth rate of 6.7%
from 2023 to 2033.
For More Insights on this Market, Get A Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-823
Competitive Landscape for the Contrast Media Injectors Market
- Mallinckrodt
(Guerbet SA)
- GE Healthcare
- Bayer AG
- Ulrich GmbH
& Co. KG
- Bracco Imaging
S.p.A
- Medtron
- NemotoKyorindo
Co. Ltd
- Shenzhen Anke
High-tech Co. Ltd
- Sino
Medical-device Technology Co., Ltd
- Apollo RT Co.,
Ltd
Recent Developments in the Contrast Media Injectors Industry
- In May 2021,
Bayer AG announced a collaboration with ArcherDX, Inc., which will focus
on the global development and commercialization of therapy-accompanying
diagnostic tests – also known as companion diagnostics (CDx) – for
Vitrakvi™ (larotrectinib), based on next-generation sequencing.
- In May 2019,
the Ulrich’s CT contrast agent injector, CT motion, was made available in
the world's most important medical technology market, the U.S.
Contrast Media Injectors Market by Category
By Product Type:
- CT Injectors
- MRI Injectors
- Cardio
Injectors
By End User:
- Hospitals
- Ambulatory
Surgical Centers
- Diagnostics
Centers
- Others
Comments
Post a Comment